MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–Apimeds Pharmaceuticals US, Inc. and L?kahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
